VEGFA and congestive heart failure: The incidence of VEGF inhibitor-associated acute cardiotoxicity appears to be very rare with at most 3% of patients in a randomized trial experiencing high grade congestive heart failure as defined by the NCI common terminology criteria for adverse events [27].